{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:57:33Z","timestamp":1785859053316,"version":"3.56.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"name":"Scientific Research Project of the Education Department of Zhejiang Province","award":["Y202559992"],"award-info":[{"award-number":["Y202559992"]}]},{"name":"Zhejiang Provincial High-Level Health Talents Training Project","award":["CZ-RC2022010"],"award-info":[{"award-number":["CZ-RC2022010"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study aims to determine the risk factors of loss to follow-up (LTFU) in patients with proliferative diabetic retinopathy (PDR) undergoing pars plana vitrectomy (PPV) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Information of patients with PDR undergoing PPV at the Department of Vitreoretinal Surgery, the Eye Hospital of Wenzhou Medical University, between 2018 and 2024 was collected. LTFU was defined as at least 1 interval exceeding 3 months without a subsequent visit in the first 6 months after PPV and not having any provider encounters documented from 6 months to 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 1,234 patients with PDR after PPV, 668 (54.1%) were LTFU. Risk factors positively associated with LTFU on multivariable analysis included preoperative hemoglobin A1c 7.5% to 9.0% (odds ratio [OR], 1.88;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.018), a duration of hypertension \u226510 years (OR, 1.61;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.048), a history of chronic kidney disease or uremia (OR, 3.55;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.005), and distance between home postal code and hospital &gt;90 km (OR, 2.03;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008). Protective factors against LTFU included a history of intravitreal injection(s) in the study eye (OR, 0.67;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.041), \u22653 preoperative visits (OR, 0.62;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.011), and the use of silicone oil tamponade during vitrectomy (OR, 0.14;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The authors identified multiple factors associated with LTFU and warrant further study to confirm their results to minimize the risk of potential complications during the postoperative period.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004859","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:04:35Z","timestamp":1776261875000},"page":"1396-1406","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["LOSS TO FOLLOW-UP IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY AFTER PARS PLANA VITRECTOMY"],"prefix":"10.1097","volume":"46","author":[{"given":"Zhiqing","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-20260717","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2522\/ptj.20080020","article-title":"Epidemiology of diabetes and diabetes-related complications","volume":"88","author":"Deshpande","year":"2008","journal-title":"Phys Ther"},{"key":"R4-20260717","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20260717","first-page":"CD013775","article-title":"Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy","volume":"2","author":"Perais","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-20260717","doi-asserted-by":"crossref","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","article-title":"Diabetic retinopathy","volume":"2","author":"Wong","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R7-20260717","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0002-9394(98)00309-2","article-title":"Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early treatment diabetic retinopathy study research group","volume":"127","author":"Fong","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R8-20260717","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/ICU.0000000000000760","article-title":"Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature","volume":"32","author":"Berrocal","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"R9-20260717","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00417-004-0977-9","article-title":"Surgical treatment of diabetic retinopathy","volume":"242","author":"Helbig","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R10-20260717","first-page":"535","article-title":"Anti-VEGF therapy for diabetic eye diseases","volume":"6","author":"Bahrami","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R11-20260717","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/IIO.0000000000000027","article-title":"Current management of vitreous hemorrhage due to proliferative diabetic retinopathy","volume":"54","author":"El Annan","year":"2014","journal-title":"Int Ophthalmol Clin"},{"key":"R12-20260717","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2019.03.005","article-title":"Anti-vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions","volume":"204","author":"Wubben","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R13-20260717","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajo.2024.06.024","article-title":"Impact of social vulnerability index on the development of severe visual impairment or blindness from glaucoma","volume":"267","author":"Swaminathan","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R14-20260717","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamaophthalmol.2024.1207","article-title":"Place-based measures of inequity and vision difficulty and blindness","volume":"142","author":"Hicks","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R15-20260717","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamaophthalmol.2022.4566","article-title":"Association of socioeconomic, demographic, and health care access disparities with severe visual impairment in the US","volume":"140","author":"Besagar","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R17-20260717","first-page":"99","article-title":"Evidence-based guidelines for diagnosis and treatment of diabetic retinopathy in China (2022)","volume":"39","year":"2023","journal-title":"Chin J Ocul Fundus Dis"},{"key":"R18-20260717","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections","volume":"125","author":"Obeid","year":"2018","journal-title":"Ophthalmology"},{"key":"R19-20260717","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.oret.2024.04.016","article-title":"Loss to follow up in patients with proliferative diabetic retinopathy treated with anti-VEGF therapy and\/or panretinal photocoagulation in the United States","volume":"8","author":"Khurana","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R20-20260717","doi-asserted-by":"crossref","first-page":"7691724","DOI":"10.1155\/2020\/7691724","article-title":"Causes and clinical impact of loss to follow-up in patients with proliferative diabetic retinopathy","volume":"2020","author":"Abdelmotaal","year":"2020","journal-title":"J Ophthalmol"},{"key":"R21-20260717","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00417-019-04414-y","article-title":"Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage","volume":"257","author":"Angermann","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R22-20260717","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/IAE.0000000000003540","article-title":"Increased distance from the clinic leads to higher loss to follow-up after pars plana vitrectomy in diabetic patients","volume":"42","author":"Deans","year":"2022","journal-title":"Retina"},{"key":"R23-20260717","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jamaophthalmol.2023.0723","article-title":"Association between social determinants of health and examination-based vision loss vs self-reported vision measures","volume":"141","author":"Alfaro Hudak","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R24-20260717","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jacc.2013.04.031","article-title":"Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality","volume":"62","author":"Nichols","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R25-20260717","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2337\/dc08-0138","article-title":"Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study","volume":"31","author":"Kornum","year":"2008","journal-title":"Diabetes Care"},{"key":"R26-20260717","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1093\/ndt\/gfh540","article-title":"The growing volume of diabetes-related dialysis: a population based study","volume":"19","author":"Lok","year":"2004","journal-title":"Nephrol Dial Transpl"},{"key":"R27-20260717","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3928\/23258160-20210330-04","article-title":"Follow-up appointment delay in diabetic macular edema patients","volume":"52","author":"Agarwal","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R28-20260717","first-page":"A10","article-title":"Predictors of dropouts from a San Diego diabetes program: a case control study","volume":"1","author":"Benoit","year":"2004","journal-title":"Prev Chronic Dis"},{"key":"R29-20260717","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1265\/ehpm.11.115","article-title":"Personal features and dropout from diabetic care","volume":"11","author":"Masuda","year":"2006","journal-title":"Environ Health Prev Med"},{"key":"R30-20260717","doi-asserted-by":"crossref","first-page":"e092013","DOI":"10.1136\/bmjopen-2024-092013","article-title":"Association of dropout history and HbA1c levels with subsequent dropout risk in patients with diabetes: a secondary analysis of the Japan Diabetes Outcome Intervention Trial-2 Large-Scale Trial 008 (J-DOIT2-LT008)","volume":"15","author":"Goto","year":"2025","journal-title":"BMJ Open"},{"key":"R31-20260717","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ajo.2020.03.023","article-title":"Predictors of lost to follow-up in patients being treated for proliferative diabetic retinopathy","volume":"216","author":"Green","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R32-20260717","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ajo.2019.10.012","article-title":"Noncompliance in prospective retina clinical trials: analysis of factors predicting loss to follow-up","volume":"210","author":"Zhou","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R33-20260717","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1370\/afm.4","article-title":"Descriptions of barriers to self-care by persons with comorbid chronic diseases","volume":"1","author":"Bayliss","year":"2003","journal-title":"Ann Fam Med"},{"key":"R34-20260717","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/089826439100300101","article-title":"Self-management of chronic disease by older adults: a review and questions for research","volume":"3","author":"Clark","year":"1991","journal-title":"J Aging Health"},{"key":"R35-20260717","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00592-020-01513-9","article-title":"Expectations and fears of patients with diabetes and macular edema treated by intravitreal injections","volume":"57","author":"Fajnkuchen","year":"2020","journal-title":"Acta Diabetol"},{"key":"R36-20260717","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/IAE.0000000000003911","article-title":"Characteristics of participants in diabetic retinopathy clinical research clinical trials who were lost to follow-up","volume":"44","author":"Bowe","year":"2024","journal-title":"Retina"},{"key":"R37-20260717","doi-asserted-by":"crossref","first-page":"e2450942","DOI":"10.1001\/jamanetworkopen.2024.50942","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy or diabetic macular edema","volume":"7","author":"Huang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R38-20260717","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.pec.2015.12.010","article-title":"Automated alerts and reminders targeting patients: a review of the literature","volume":"99","author":"Perri-Moore","year":"2016","journal-title":"Patient Educ Couns"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:04:01Z","timestamp":1785855841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004859","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}